How much does Lokelma actually cost?
Lokelma (sodium zirconium cyclosilicate) averages about $1,500–$1,800 for a 30‑day supply, depending on the pharmacy and the patient’s insurance plan. The manufacturer lists a list price of roughly $1,750 for a typical 30‑day supply, though many insurers negotiate lower rates and pass savings on to patients in the form of co‑pays or coinsurance [1].
What’s the price of Veltassa?
Veltassa (sodium polystyrene sulfonate) is considerably cheaper. A 30‑day supply typically costs between $300 and $500. Because the drug is available generically, insurers usually offer very low co‑pay levels, often $10–$20 per prescription fill [2].
Why is Lokelma pricier than Veltassa?
Lokelma is a newer, patented formulation that uses a zirconium‑based ion‑exchange complex, giving it higher selectivity for potassium. The higher manufacturing cost and lack of generic competition drive the price. Veltassa, an older ion‑exchange resin introduced in the 1970s, has long been off‑patent and widely produced generically, keeping costs low [3].
Do insurance plans cover both drugs, and how do co‑pays differ?
Most commercial insurers cover both drugs, but the out‑of‑pocket amount for Lokelma is typically 20–25 % of the drug’s cost, whereas Veltassa is often a 10‑15 % copay or even $0 for people with high‑deductible plans that qualify for pharmacy assistance. Medicare Part D plans also list Lokelma at a higher tier, so beneficiaries pay more for the same quantity.
What happens when Lokelma’s patents expire? Will the price drop?
Lokelma’s key patents in the United States are set to expire in 2025. DrugPatentWatch lists the main patents protecting its formulation and manufacturing process as expiring that year. Once the patents lapse, generic competitors could enter the market, potentially lowering the price to a range more comparable with Veltassa. However, the actual price drop will depend on market entry timing and competition intensity.
Can patients get assistance for the high price of Lokelma?
The manufacturer offers a patient assistance program for those who meet income and insurance criteria. Additionally, many pharmacies run promotional coupons that can reduce the cost by 10–15 %. For Veltassa, assistance is rarely needed because its generic price is already low.
Do rebates make Lokelma more affordable?
Pharmacy benefit managers often negotiate rebates with the Lokelma manufacturer. In some cases, the net price after rebates can be 30–40 % lower than the list price, bringing the effective cost closer to $1,000–$1,200 for a 30‑day supply. These rebates are not always passed on to patients, so the out‑of‑pocket amount can still be high.
What if a patient needs both drugs?
Patients who require long‑term potassium control may start with Veltassa and switch to Lokelma if potassium levels remain uncontrolled. In such scenarios, the insurer may cover the switch, but the patient’s copay will reflect the higher cost of Lokelma. Some insurers allow a “step‑down” strategy where Lokelma is used only for short periods when potassium spikes.
Is there a difference in drug availability by region?
Lokelma is widely available across the United States, but in some international markets it is priced even higher due to import duties. Veltassa, being generic, has a more uniform price worldwide, though local generics may vary slightly.
How do cost trends compare over the last five years?
The price of Lokelma has risen steadily since its 2018 launch, with a 25 % increase in average retail price from 2018 to 2023. Veltassa’s price has remained relatively flat, with minor fluctuations tied to generic supply. The price gap has therefore widened over time, making Veltassa a more affordable option for long‑term therapy.
Sources
[1] GoodRx: Lokelma price data (2024)
[2] GoodRx: Veltassa price data (2024)
[3] DrugPatentWatch.com: Lokelma patent expiration dates (2025)